Research programme: mRNA based therapeutics - Omega Therapeutics
Latest Information Update: 28 May 2025
At a glance
- Originator Omega Therapeutics
- Class Anti-inflammatories; Eye disorder therapies; Hepatoprotectants; RNA; Skin disorder therapies
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Corneal disorders
- No development reported Alopecia; Idiopathic pulmonary fibrosis; Liver disorders; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Alopecia in USA (Topical)
- 28 May 2025 No recent reports of development identified for preclinical development in Liver-disorders in USA (IV)
- 28 May 2025 No recent reports of development identified for preclinical development in SARS-COV-2 acute respiratory disease in USA (IV)